SGX94: Preliminary Phase II data

Preliminary data from a double-blind, placebo-controlled, U.S. Phase II trial in 111 patients undergoing chemoradiation for head and neck cancer showed that 1.5 mg/kg IV SGX942 reduced the median dura...